Literature DB >> 21444793

IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo.

Nicholas D Huntington1, Nuno L Alves, Nicolas Legrand, Annick Lim, Helene Strick-Marchand, Jean-Jacques Mention, Ariane Plet, Kees Weijer, Yannick Jacques, Pablo D Becker, Carlos Guzman, Patrick Soussan, Dina Kremsdorf, Hergen Spits, James P Di Santo.   

Abstract

Cytokine immunotherapies targeting T lymphocytes are attractive clinical interventions against viruses and tumors. In the mouse, the homeostasis of memory α/β CD8(+) T cells and natural killer (NK) cells is significantly improved with increased IL-15 bioavailability. In contrast, the role of "transpresented" IL-15 on human T-cell development and homeostasis in vivo is unknown. We found that both CD8 and CD4 T cells in human immune system (HIS) mice are highly sensitive to transpresented IL-15 in vivo, with both naïve (CD62L(+)CD45RA(+)) and memory phenotype (CD62L(-)CD45RO(+)) subsets being significantly increased following IL-15 "boosting." The unexpected global improvement in human T-cell homeostasis involved enhanced proliferation and survival of both naïve and memory phenotype peripheral T cells, which potentiated B-cell responses by increasing the frequency of antigen-specific responses following immunization. Transpresented IL-15 did not modify T-cell activation patterns or alter the global T-cell receptor (TCR) repertoire diversity. Our results indicate an unexpected effect of IL-15 on human T cells in vivo, in particular on CD4(+) T cells. As IL-15 promotes human peripheral T-cell homeostasis and increases the frequency of neutralizing antibody responses in HIS mice, IL-15 immunotherapy could be envisaged as a unique approach to improve vaccine responses in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444793      PMCID: PMC3076818          DOI: 10.1073/pnas.1019167108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.

Authors:  A I Chapoval; J A Fuller; S G Kremlev; S J Kamdar; R Evans
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

2.  Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques.

Authors:  Yvonne M Mueller; Constantinos Petrovas; Paul M Bojczuk; Ioannis D Dimitriou; Brigitte Beer; Peter Silvera; Francois Villinger; J Scott Cairns; Edward J Gracely; Mark G Lewis; Peter D Katsikis
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Authors:  Erwan Mortier; Agnès Quéméner; Patricia Vusio; Inken Lorenzen; Yvan Boublik; Joachim Grötzinger; Ariane Plet; Yannick Jacques
Journal:  J Biol Chem       Date:  2005-11-11       Impact factor: 5.157

Review 4.  Experimental models to study development and function of the human immune system in vivo.

Authors:  Nicolas Legrand; Kees Weijer; Hergen Spits
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

5.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.

Authors:  Y Shinkai; G Rathbun; K P Lam; E M Oltz; V Stewart; M Mendelsohn; J Charron; M Datta; F Young; A M Stall
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

6.  Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells.

Authors:  Ramon Gimeno; Kees Weijer; Arie Voordouw; Christel H Uittenbogaart; Nicolas Legrand; Nuno L Alves; Erwin Wijnands; Bianca Blom; Hergen Spits
Journal:  Blood       Date:  2004-08-19       Impact factor: 22.113

7.  Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain.

Authors:  J P DiSanto; W Müller; D Guy-Grand; A Fischer; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

8.  Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.

Authors:  Ryan M Teague; Blythe D Sather; Jilian A Sacks; Maria Z Huang; Michelle L Dossett; Junko Morimoto; Xiaoxio Tan; Susan E Sutton; Michael P Cooke; Claes Ohlén; Philip D Greenberg
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

9.  Humanized mice: are we there yet?

Authors:  Francesca Macchiarini; Markus G Manz; A Karolina Palucka; Leonard D Shultz
Journal:  J Exp Med       Date:  2005-11-21       Impact factor: 14.307

10.  A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary natural killer cells.

Authors:  Nicholas D Huntington; Yuekang Xu; Stephen L Nutt; David M Tarlinton
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

View more
  34 in total

1.  A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion.

Authors:  Nicolas Legrand; Gisela J van der Velden; Raphaël Ho Tsong Fang; Marc Douaisi; Kees Weijer; Atze T Das; Bianca Blom; Christel H Uittenbogaart; Ben Berkhout; Mireille Centlivre
Journal:  J Gen Virol       Date:  2012-05-30       Impact factor: 3.891

2.  Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice.

Authors:  Eva Billerbeck; Rachael N Labitt; Kevin Vega; Natalia Frias-Staheli; Marcus Dorner; Jing W Xiao; Charles M Rice; Alexander Ploss
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

3.  Astrocytes fuel the fire of lymphocyte toxicity after stroke.

Authors:  Meaghan Roy-O'Reilly; Louise D McCullough
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-06       Impact factor: 11.205

Review 4.  Engineering humanized mice for improved hematopoietic reconstitution.

Authors:  Adam C Drake; Qingfeng Chen; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2012-03-19       Impact factor: 11.530

Review 5.  Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases.

Authors:  Iurii Koboziev; Yava Jones-Hall; John F Valentine; Cynthia Reinoso Webb; Kathryn L Furr; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

Review 6.  Homeostatic expansion as a barrier to lymphocyte depletion strategies.

Authors:  Nicholas A Zwang; Laurence A Turka
Journal:  Curr Opin Organ Transplant       Date:  2014-08       Impact factor: 2.640

7.  Replacing mouse BAFF with human BAFF does not improve B-cell maturation in hematopoietic humanized mice.

Authors:  Julie Lang; Bicheng Zhang; Margot Kelly; Jacob N Peterson; Jacob Barbee; Brian M Freed; James P Di Santo; Jennifer L Matsuda; Raul M Torres; Roberta Pelanda
Journal:  Blood Adv       Date:  2017-12-19

Review 8.  Improved mouse models and advanced genetic and genomic technologies for the study of neutrophils.

Authors:  Vishnu Hosur; Daniel A Skelly; Christopher Francis; Benjamin E Low; Vivek Kohar; Lisa M Burzenski; Mansoor M Amiji; Leonard D Shultz; Michael V Wiles
Journal:  Drug Discov Today       Date:  2020-05-05       Impact factor: 7.851

9.  Opposing chemokine gradients control human thymocyte migration in situ.

Authors:  Joanna Halkias; Heather J Melichar; Kayleigh T Taylor; Jenny O Ross; Bonnie Yen; Samantha B Cooper; Astar Winoto; Ellen A Robey
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

10.  Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells.

Authors:  Wolfgang Jungraithmayr; Laura Codarri; Gregory Bouchaud; Carsten Krieg; Onur Boyman; Gabor Gyülvészi; Burkhard Becher; Walter Weder; Christian Münz
Journal:  Am J Respir Crit Care Med       Date:  2013-06-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.